Korean Journal of Psychosomatic Medicine (정신신체의학)

Korean Psychosomatic Society (한국정신신체의학회)
권호 표지
DOI QR코드

DOI QR Code

Fibromyalgia from the Psychiatric Perspective

정신과적 관점에서의 섬유근통

  • Lee, Yunna (Department of Psychiatry, Kosin University Gospel Hospital) ;
  • Lee, Sang-Shin (Department of Psychiatry, Kosin University Gospel Hospital) ;
  • Kim, Hyunseuk (Department of Child and Adolescent Psychiatry, National Center for Mental Health) ;
  • Kim, Hochan (Department of Psychiatry, Kosin University Gospel Hospital)
  • 이윤나 (고신대학교복음병원 정신건강의학과) ;
  • 이상신 (고신대학교복음병원 정신건강의학과) ;
  • 김현석 (국립정신건강센터 소아청소년정신과) ;
  • 김호찬 (고신대학교복음병원 정신건강의학과)
  • Received : 2020.09.23
  • Accepted : 2020.10.19
  • Published : 2020.12.31
Download PDF
⟨ Previous Next ⟩

Abstract

Fibromyalgia is a disorder characterized by the core symptom of chronic widespread pain, along with fatigue, sleep disturbances, mood changes, and cognitive difficulties. The etiology of fibromyalgia involves a combination of biological factors, such as genetic vulnerability, alterations in pain processing and stress response system ; psychological factors, such as anxiety, depression, anger, and perceived stress ; environmental factors, such as infections, febrile diseases, and trauma. Central sensitization, which is amplified in the process of sensory stimulation, has been emphasized as a key etiological factor, as supported by enhanced wind-up, delayed aftersensation, decreased nociceptive flexion reflex threshold and functional imaging studies. Several guidelines recommend that a multimodal approach be used to treat fibromyalgia, including both pharmacological and non-pharmacological treatments, tailored to each individual, and that clinicians should provide an intellectual framework through sufficient education and emphasis on the importance of self-management. The prevalence of mood disorders, anxiety disorders, and other psychiatric problems is 7-9 times higher in patients with fibromyalgia than in the general population ; moreover, the association between fibromyalgia and certain psychopathologies or sleep problems has also been suggested. Since psychiatric problems, with shared vulnerabilities and risk factors, interact with fibromyalgia bidirectionally and also affect the disease course, an integrated management approach is needed to determine the risk of comorbidities.

섬유근통은 피로, 수면장애, 기분변화, 인지장애 및 만성 전신통증을 핵심 증상으로 하는 질환이다. 섬유근통은 유전적 취약성, 통증 처리과정 및 스트레스 반응 체계의 변화 등을 포함하는 생물학적 요인과 불안, 우울, 분노, 스트레스 등의 심리적 요인, 그리고 감염, 발열 질환, 외상 등의 환경적 요인이 함께 작용하여 발생하는 것으로 알려져 있으며, 핵심 병인으로 감각 자극이 인식되는 과정에서 증폭되어 통증이 증진되는 중추성 감작의 역할이 강조되고 있다. 가이드라인들은 개별 환자의 필요에 따라 선택된 다원적 접근을 권고하며, 임상의는 충분한 교육을 통해 지적 이해의 틀을 제공하고 자기 관리의 중요성을 강조해야 한다. 섬유근통에서 정신건강 문제의 유병률은 일반인구집단의 7~9배로 유의하게 높으며, 특정 정신병리 및 수면장애와의 관련성도 제기되고 있다. 정신과적 상태는 섬유근통과 양방향성 상호작용을 하며 경과에 영향을 주고, 취약성을 공유하며 서로의 위험 요인으로 작용할 수 있으므로, 동반질환을 면밀히 평가하여 보다 통합적인 관리가 필요할 것이다.

Keywords

References

  1. Clauw DJ. Fibromyalgia: a clinical review. Jama 2014;311:1547-1555. https://doi.org/10.1001/jama.2014.3266
  2. Queiroz LP. Worldwide epidemiology of fibromyalgia. Curr Pain Headache Rep 2013;17:356. https://doi.org/10.1007/s11916-013-0356-5
  3. Hauser W, Ablin J, Fitzcharles MA, Littlejohn G, Luciano JV, Usui C, Walitt B. Fibromyalgia. Nat Rev Dis Primers 2015;1:15022. https://doi.org/10.1038/nrdp.2015.22
  4. Kim C, Kim H, Kim J. Prevalence of chronic widespread pain and fibromyalgia syndrome: a Korean hospital-based study. Rheumatol Int 2012;32:3435-3442. https://doi.org/10.1007/s00296-011-2195-1
  5. Lee HJ, Choi E, Nahm FS, Choi SS, Kim YH, Moon JY, Kim SH, Cho CW, Lee PB. Prevalence of fibromyalgia in fourteen Korean tertiary care university hospital pain clinics. J Pain Res 2018;11:2417-2423. https://doi.org/10.2147/JPR.S172221
  6. Hauser W, Schild S, Kosseva M, Hayo S, von Wilmowski H, Alten R, Langhorst J, Hofmann W, Maus J, Glaesmer H. Validation of the German version of the Regional Pain Scale for the diagnosis of fibromyalgia syndrome. Schmerz 2010;24: 226-235. https://doi.org/10.1007/s00482-010-0931-1
  7. Kudlow PA, Rosenblat JD, Weissman CR, Cha DS, Kakar R, McIntyre RS, Sharma V. Prevalence of fibromyalgia and co-morbid bipolar disorder: a systematic review and meta-analysis. J Affect Disord 2015;188:134-142. https://doi.org/10.1016/j.jad.2015.08.030
  8. Crofford LJ. Chapter 52-Fibromyalgia. In: Firestein GS, Budd RC, Gabriel SE, McInnes IB, O'Dell JR, editors. Kelley and Firestein's Textbook of Rheumatology (Tenth Edition): Elsevier;2017. p.768-783.e763.
  9. 대한류마티스학회. 류마티스학. 2판. ed. 서울: 범문에듀케이션; 2018.
  10. Mogil JS. Pain genetics: past, present and future. Trends Genet 2012;28:258-266. https://doi.org/10.1016/j.tig.2012.02.004
  11. Arnold LM, Hudson JI, Hess EV, Ware AE, Fritz DA, Auchenbach MB, Starck LO, Keck PE Jr. Family study of fibromyalgia. Arthritis Rheum 2004;50:944-952. https://doi.org/10.1002/art.20042
  12. Arnold LM, Fan J, Russell IJ, Yunus MB, Khan MA, Kushner I, Olson JM, Iyengar SK. The fibromyalgia family study: a genome-wide linkage scan study. Arthritis Rheum 2013;65: 1122-1128. https://doi.org/10.1002/art.37842
  13. D'Agnelli S, Arendt-Nielsen L, Gerra MC, Zatorri K, Boggiani L, Baciarello M, Bignami E. Fibromyalgia: Genetics and epigenetics insights may provide the basis for the development of diagnostic biomarkers. Mol Pain 2019;15: 1744806918819944.
  14. Park DJ, Kim SH, Nah SS, Lee JH, Kim SK, Lee YA, Hong SJ, Kim HS, Lee HS, Kim HA, Joung CI, Kim SH, Lee SS. Association between brain-derived neurotrophic factor gene polymorphisms and fibromyalgia in a Korean population: a multicenter study. Arthritis Res Ther 2018;20:220. https://doi.org/10.1186/s13075-018-1726-5
  15. Menzies V, Lyon DE, Archer KJ, Zhou Q, Brumelle J, Jones KH, Gao G, York TP, Jackson-Cook C. Epigenetic alterations and an increased frequency of micronuclei in women with fibromyalgia. Nurs Res Pract 2013;2013:795784. https://doi.org/10.1155/2013/795784
  16. Ciampi de Andrade D, Maschietto M, Galhardoni R, Gouveia G, Chile T, Victorino Krepischi AC, Dale CS, Brunoni AR, Parravano DC, Cueva Moscoso AS, Raicher I, Kaziyama HHS, Teixeira MJ, Brentani HP. Epigenetics insights into chronic pain: DNA hypomethylation in fibromyalgia-a controlled pilot-study. Pain 2017;158:1473-1480. https://doi.org/10.1097/j.pain.0000000000000932
  17. Woolf CJ. Central sensitization: implications for the diagnosis and treatment of pain. Pain 2011;152:S2-15. https://doi.org/10.1016/j.pain.2010.09.030
  18. Staud R, Vierck CJ, Cannon RL, Mauderli AP, Price DD. Abnormal sensitization and temporal summation of second pain (wind-up) in patients with fibromyalgia syndrome. Pain 2001;91:165-175. https://doi.org/10.1016/S0304-3959(00)00432-2
  19. Staud R, Weyl EE, Riley JL 3rd, Fillingim RB. Slow temporal summation of pain for assessment of central pain sensitivity and clinical pain of fibromyalgia patients. PLoS One 2014; 9:e89086. https://doi.org/10.1371/journal.pone.0089086
  20. Hachisuka J, Omori Y, Chiang MC, Gold MS, Koerber HR, Ross SE. Wind-up in lamina I spinoparabrachial neurons: a role for reverberatory circuits. Pain 2018;159:1484-1493. https://doi.org/10.1097/j.pain.0000000000001229
  21. Desmeules JA, Cedraschi C, Rapiti E, Baumgartner E, Finckh A, Cohen P, Dayer P, Vischer TL. Neurophysiologic evidence for a central sensitization in patients with fibromyalgia. Arthritis Rheum 2003;48:1420-1429. https://doi.org/10.1002/art.10893
  22. Hauser W, Urrutia G, Tort S, Uceyler N, Walitt B. Serotonin and noradrenaline reuptake inhibitors (SNRIs) for fibromyalgia syndrome. Cochrane Database Syst Rev 2013:Cd010292.
  23. Harris RE, Clauw DJ, Scott DJ, McLean SA, Gracely RH, Zubieta JK. Decreased central mu-opioid receptor availability in fibromyalgia. J Neurosci 2007;27:10000-10006. https://doi.org/10.1523/JNEUROSCI.2849-07.2007
  24. Younger J, Mackey S. Fibromyalgia symptoms are reduced by low-dose naltrexone: a pilot study. Pain Med 2009;10:663-672. https://doi.org/10.1111/j.1526-4637.2009.00613.x
  25. Harris RE, Sundgren PC, Craig AD, Kirshenbaum E, Sen A, Napadow V, Clauw DJ. Elevated insular glutamate in fibromyalgia is associated with experimental pain. Arthritis Rheum 2009;60:3146-3152. https://doi.org/10.1002/art.24849
  26. Gracely RH, Petzke F, Wolf JM, Clauw DJ. Functional magnetic resonance imaging evidence of augmented pain processing in fibromyalgia. Arthritis Rheum 2002;46:1333-1343. https://doi.org/10.1002/art.10225
  27. Cook DB, Lange G, Ciccone DS, Liu WC, Steffener J, Natelson BH. Functional imaging of pain in patients with primary fibromyalgia. J Rheumatol 2004;31:364-378.
  28. Lopez-Sola M, Woo CW, Pujol J, Deus J, Harrison BJ, Monfort J, Wager TD. Towards a neurophysiological signature for fibromyalgia. Pain 2017;158:34-47. https://doi.org/10.1097/j.pain.0000000000000707
  29. Uceyler N, Hauser W, Sommer C. Systematic review with meta-analysis: cytokines in fibromyalgia syndrome. BMC Musculoskelet Disord 2011;12:245. https://doi.org/10.1186/1471-2474-12-245
  30. Milligan ED, Watkins LR. Pathological and protective roles of glia in chronic pain. Nat Rev Neurosci 2009;10:23-36. https://doi.org/10.1038/nrn2533
  31. Martinez-Martinez LA, Mora T, Vargas A, Fuentes-Iniestra M, Martinez-Lavin M. Sympathetic nervous system dysfunction in fibromyalgia, chronic fatigue syndrome, irritable bowel syndrome, and interstitial cystitis: a review of case-control studies. J Clin Rheumatol 2014;20:146-150. https://doi.org/10.1097/RHU.0000000000000089
  32. Zamuner AR, Barbic F, Dipaola F, Bulgheroni M, Diana A, Atzeni F, Marchi A, Sarzi-Puttini P, Porta A, Furlan R. Relationship between sympathetic activity and pain intensity in fibromyalgia. Clin Exp Rheumatol 2015;33:S53-57.
  33. Eisenlohr-Moul TA, Crofford LJ, Howard TW, Yepes JF, Carlson CR, de Leeuw R. Parasympathetic reactivity in fibromyalgia and temporomandibular disorder: associations with sleep problems, symptom severity, and functional impairment. J Pain 2015;16:247-257. https://doi.org/10.1016/j.jpain.2014.12.005
  34. Eller-Smith OC, Nicol AL, Christianson JA. Potential mechanisms underlying centralized pain and emerging therapeutic interventions. Front Cell Neurosci 2018;12:35.
  35. Galvez-Sanchez CM, Duschek S, Reyes Del Paso GA. Psychological impact of fibromyalgia: current perspectives. Psychol Res Behav Manag 2019;12:117-127. https://doi.org/10.2147/PRBM.S178240
  36. Choy EH. The role of sleep in pain and fibromyalgia. Nat Rev Rheumatol 2015;11:513-520. https://doi.org/10.1038/nrrheum.2015.56
  37. Cetin B, Gulec H, Toktas HE, Ulutas O, Yilmaz SG, Isbir T. Objective measures of sleep in fibromyalgia syndrome: Relationship to clinical, psychiatric, and immunological variables. Psychiatry Res 2018;263:125-129. https://doi.org/10.1016/j.psychres.2018.02.057
  38. Palagini L, Carmassi C, Conversano C, Gesi C, Bazzichi L, Giacomelli C, Dell'Osso L. Transdiagnostic factors across fibromyalgia and mental disorders: sleep disturbances may play a key role. A clinical review. Clin Exp Rheumatol 2016;34: S140-144.
  39. Martinez-Lavin M. Fibromyalgia and small fiber neuropathy: the plot thickens! Clin Rheumatol 2018;37:3167-3171. https://doi.org/10.1007/s10067-018-4300-2
  40. Kayhan F, Kucuk A, Satan Y, Ilgun E, Arslan S, Ilik F. Sexual dysfunction, mood, anxiety, and personality disorders in female patients with fibromyalgia. Neuropsychiatr Dis Treat 2016;12:349-355. https://doi.org/10.2147/ndt.s99160
  41. Loge-Hagen JS, Sæle A, Juhl C, Bech P, Stenager E, Mellentin AI. Prevalence of depressive disorder among patients with fibromyalgia: systematic review and meta-analysis. J Affect Disord 2019;245:1098-1105. https://doi.org/10.1016/j.jad.2018.12.001
  42. Walitt B, Nahin RL, Katz RS, Bergman MJ, Wolfe F. The prevalence and characteristics of fibromyalgia in the 2012 national health interview survey. PLoS One 2015;10:e0138024. https://doi.org/10.1371/journal.pone.0138024
  43. Cunningham NR, Tran ST, Lynch-Jordan AM, Ting TV, Sil S, Strotman D, Noll JG, Powers SW, Arnold LM, Kashikar-Zuck S. Psychiatric disorders in young adults diagnosed with juvenile fibromyalgia in adolescence. J Rheumatol 2015; 42:2427-2433. https://doi.org/10.3899/jrheum.141369
  44. Lange M, Petermann F. Influence of depression on fibromyalgia: a systematic review. Schmerz 2010;24:326-333. https://doi.org/10.1007/s00482-010-0937-8
  45. Novo R, Gonzalez B, Peres R, Aguiar P. A meta-analysis of studies with the minnesota multiphasic personality inventory in fibromyalgia patients. Personality and Individual Differences 2017;116:96-108. https://doi.org/10.1016/j.paid.2017.04.026
  46. Attademo L, Bernardini F. Prevalence of personality disorders in patients with fibromyalgia: a brief review. Prim Health Care Res Dev 2018;19:523-528. https://doi.org/10.1017/S1463423617000871
  47. Garcia-Fontanals A, Portell M, Garcia-Blanco S, Poca-Dias V, Garcia-Fructuoso F, Lopez-Ruiz M, Gutierrez-Rosado T, Goma IFM, Deus J. Vulnerability to psychopathology and dimensions of personality in patients with fibromyalgia. Clin J Pain 2017;33:991-997. https://doi.org/10.1097/AJP.0000000000000506
  48. Chinn S, Caldwell W, Gritsenko K. Fibromyalgia pathogenesis and treatment options update. Curr Pain Headache Rep 2016;20:25. https://doi.org/10.1007/s11916-016-0556-x
  49. Vincent A, Whipple MO, Rhudy LM. Fibromyalgia flares: a qualitative analysis. Pain Med 2016;17:463-468.
  50. Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, Goldenberg DL, Tugwell P, Campbell SM, Abeles M, Clark P, et al. The american college of rheumatology 1990 criteria for the classification of fibromyalgia. report of the multicenter criteria committee. Arthritis Rheum 1990;33:160-172. https://doi.org/10.1002/art.1780330203
  51. Wolfe F, Clauw DJ, Fitzcharles MA, Goldenberg DL, Katz RS, Mease P, Russell AS, Russell IJ, Winfield JB, Yunus MB. The American college of rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care Res (Hoboken) 2010;62:600-610. https://doi.org/10.1002/acr.20140
  52. Wolfe F, Clauw DJ, Fitzcharles MA, Goldenberg DL, Hauser W, Katz RL, Mease PJ, Russell AS, Russell IJ, Walitt B. 2016 Revisions to the 2010/2011 fibromyalgia diagnostic criteria. Semin Arthritis Rheum 2016;46:319-329. https://doi.org/10.1016/j.semarthrit.2016.08.012
  53. Wolfe F, Clauw DJ, Fitzcharles MA, Goldenberg DL, Hauser W, Katz RS, Mease P, Russell AS, Russell IJ, Winfield JB. Fibromyalgia criteria and severity scales for clinical and epidemiological studies: a modification of the ACR Preliminary Diagnostic Criteria for Fibromyalgia. J Rheumatol 2011;38: 1113-1122. https://doi.org/10.3899/jrheum.100594
  54. Wolfe F, Hauser W. Fibromyalgia diagnosis and diagnostic criteria. Ann Med 2011;43:495-502. https://doi.org/10.3109/07853890.2011.595734
  55. Macfarlane GJ, Kronisch C, Dean LE, Atzeni F, Hauser W, FluB E, Choy E, Kosek E, Amris K, Branco J, Dincer F, Leino-Arjas P, Longley K, McCarthy GM, Makri S, Perrot S, Sarzi-Puttini P, Taylor A, Jones GT. EULAR revised recommendations for the management of fibromyalgia. Ann Rheum Dis 2017;76:318-328. https://doi.org/10.1136/annrheumdis-2016-209724
  56. Fitzcharles MA, Ste-Marie PA, Goldenberg DL, Pereira JX, Abbey S, Choinière M, Ko G, Moulin DE, Panopalis P, Proulx J, Shir Y. 2012 Canadian Guidelines for the diagnosis and management of fibromyalgia syndrome: executive summary. Pain Res Manag 2013;18:119-126. https://doi.org/10.1155/2013/918216
  57. Thieme K, Mathys M, Turk DC. Evidenced-based guidelines on the treatment of fibromyalgia patients: are they consistent and if not, why not? have effective psychological treatments been overlooked? J Pain 2017;18:747-756. https://doi.org/10.1016/j.jpain.2016.12.006
  58. Nuesch E, Hauser W, Bernardy K, Barth J, Juni P. Comparative efficacy of pharmacological and non-pharmacological interventions in fibromyalgia syndrome: network meta-analysis. Ann Rheum Dis 2013;72:955-962. https://doi.org/10.1136/annrheumdis-2011-201249
  59. Hauser W, Wolfe F, Tolle T, Uceyler N, Sommer C. The role of antidepressants in the management of fibromyalgia syndrome: a systematic review and meta-analysis. CNS Drugs 2012;26:297-307. https://doi.org/10.2165/11598970-000000000-00000
  60. Uceyler N, Sommer C, Walitt B, Hauser W. Anticonvulsants for fibromyalgia. Cochrane Database Syst Rev 2013:Cd010782.
  61. Hauser W, Bernardy K, Uceyler N, Sommer C. Treatment of fibromyalgia syndrome with gabapentin and pregabalin--a meta-analysis of randomized controlled trials. Pain 2009;145: 69-81. https://doi.org/10.1016/j.pain.2009.05.014
  62. Patten DK, Schultz BG, Berlau DJ. The safety and efficacy of low-dose naltrexone in the management of chronic pain and inflammation in multiple sclerosis, fibromyalgia, crohn's disease, and other chronic pain disorders. Pharmacotherapy 2018;38:382-389. https://doi.org/10.1002/phar.2086
  63. Gaskell H, Moore RA, Derry S, Stannard C. Oxycodone for pain in fibromyalgia in adults. Cochrane Database Syst Rev 2016;9:Cd012329.
  64. Sommer C, Hauser W, Alten R, Petzke F, Spath M, Tolle T, Uceyler N, Winkelmann A, Winter E, Bar KJ. [Drug therapy of fibromyalgia syndrome. Systematic review, meta-analysis and guideline]. Schmerz 2012;26:297-310. https://doi.org/10.1007/s00482-012-1172-2
  65. Hauser W, Walitt B, Fitzcharles MA, Sommer C. Review of pharmacological therapies in fibromyalgia syndrome. Arthritis Res Ther 2014;16:201. https://doi.org/10.1186/ar4441
  66. Bernardy K, Klose P, Welsch P, Hauser W. Efficacy, acceptability and safety of cognitive behavioural therapies in fibromyalgia syndrome-a systematic review and meta-analysis of randomized controlled trials. Eur J Pain 2018;22:242-260. https://doi.org/10.1002/ejp.1121
  67. Haugmark T, Hagen KB, Smedslund G, Zangi HA. Mindfulness- and acceptance-based interventions for patients with fibromyalgia-a systematic review and meta-analyses. PLoS One 2019;14:e0221897. https://doi.org/10.1371/journal.pone.0221897